海思科(002653.SZ)获得创新药HSK47977片药物临床试验批准

Core Viewpoint - The company received approval from the National Medical Products Administration for its drug "HSK47977," which is a novel oral BCL6 PROTAC small molecule formulation aimed at treating non-Hodgkin lymphoma [1] Group 1 - The drug HSK47977 is developed in-house by the company and targets the degradation of the BCL6 protein, which is crucial in the development and progression of tumor cells [1] - The approval signifies a significant step forward in the company's oncology pipeline, potentially enhancing its market position in cancer treatment [1]